ERBB2 and breast carcinoma: High TILs percentage (>50%) was an independent positive prognostic factor.<h4>Conclusions</h4>In patients with HER2-positive breast cancer treated with adjuvant trastuzumab, the percentage of TILs, stroma type, and PD-L1 expression are prognostically relevant.